Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.

Melanoma research - 1 Oct 2014

Bowyer Samantha E, Rao Aparna D, Lyle Megan, Sandhu Shahneen, Long Georgina V, McArthur Grant A, Raleigh Jeanette M, Hicks Rodney J, Millward Michael

Abstract excerpt

BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibito...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Extracellular Signal-Regulated MAP Kinases
Share to Fluorodeoxyglucose F18

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Neoplasm Metastasis

Share to Positron-Emission Tomography

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 24933606
DOI: 10.1097/CMR.0000000000000099

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24933606-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.PMID 24933606Read ↗

Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.Semantic proximity Read ↗

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.Semantic proximity Read ↗

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.Semantic proximity Read ↗

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.Semantic proximity Read ↗

Improved survival with MEK inhibition in BRAF-mutated melanoma.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

The role of MEK inhibitors in the treatment of metastatic melanoma.Semantic proximity Read ↗

Trametinib (GSK1120212) in the treatment of melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.